title: Opioid plasma concentration during switching from morphine to methadone: preliminary data.
abstract: Opioid switching is often used to improve the opioid response in cancer patients experiencing poor analgesia or adverse effects. However, no data are available on plasmatic changes of opioids and their metabolites during these phases, and whether there exists a relationship with the clinical events. In a prospective study of 10 consecutive cancer patients on oral morphine but with uncontrolled pain (greater >4 on a numerical scale of 0 to 10) and/or moderate to severe opioid adverse effects (on a level of 2 and 3 of a verbal scale) and not responsive to adjuvant medications, switching to oral methadone was performed using a fixed ratio of 5:1, leaving extra-doses of 1/5 of the daily dose of methadone calculated as needed. Blood samples were obtained at the same hour for four days, before the switching, and then on day 1, 2, and 3. The intensity of pain and the adverse effects were assessed daily to calculate the switching score before and after switching. Completed blood samples were obtained in 9 patients. One patient was separately considered, because of his renal impairment. Significant improvements in pain intensity as well as adverse effects within an average period of 1-2 days were observed. Morphine, morphine-6-glucuronide, and morphine-3-glucuronide were progressively cleared from plasma to almost disappear within three days. Methadone rapidly achieved a stable concentration in 1-2 days. The doses of methadone were changed, but not significantly, and tended to decrease in the following days, according to the clinical situation. The results of this study confirm the need to stop rapidly morphine, and to use a priming dose of methadone, rather than using progressive decrements and increments of morphine and methadone, respectively, during opioid switching. This method allows for a rapid clearance of morphine and its metabolites are rapidly cleared, except in patients with renal failure. Opioid plasma changes substantially overlap the clinical changes observed in these patients, in terms of benefit between analgesia and adverse effects.
authors.affiliation: Pain Relief and Palliative Care Unit, La Maddalena Cancer Center, Via S.Lorenzo 312, 90146 Palermo, Italy. terapiadeldolore@la-maddalena.it
authors.forename: S
authors.initials: S
authors.lastname: Mercadante
authors.forename: M
authors.initials: M
authors.lastname: Bianchi
authors.forename: P
authors.initials: P
authors.lastname: Villari
authors.forename: P
authors.initials: P
authors.lastname: Ferrera
authors.forename: A
authors.initials: A
authors.lastname: Casuccio
authors.forename: F
authors.initials: F
authors.lastname: Fulfaro
authors.forename: V
authors.initials: V
authors.lastname: Gebbia
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000701:Analgesics, Opioid / Q000008:administration & dosage / Q000097:blood*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008691:Methadone / Q000008:administration & dosage / Q000097:blood*; D008875:Middle Aged; D009020:Morphine / Q000008:administration & dosage / Q000097:blood*; D009369:Neoplasms / Q000150:complications; D010148:Intractable Pain / Q000097:blood* / Q000188:drug therapy* / Q000209:etiology; D011446:Prospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000701:Analgesics, Opioid; D009020:Morphine; D008691:Methadone